ReviewNigerian medical journal : journal of the Nigeria Medical Association
Types and Severity of Hearing Loss among Patients with Tuberculosis receiving Anti-Tuberculosis Treatment in Nigeria: A Single Center Study.
Review in Nigerian medical journal : journal of the Nigeria Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) is a contagious and potentially fatal infectious disease with significant global morbidity and mortality. Both the disease and some anti-TB medications have been linked to hearing loss. The study objective is to determine the Types and severity of hearing loss among patients receiving anti-tuberculosis drugs at NAUTH, Nnewi, Nigeria. Methodology: This prospective cohort study, conducted over one year at Nnamdi Azikiwe University Teaching Hospital (NAUTH) among adults enrolled in TB patients 18-60years and healthy controls using convenient sampling. GeneXpert/AFB testing was used for TB diagnosis, and pure tone audiometry was done for all participants, with follow-up assessments at 2 and 3 months for TB patients. Statistical analysis was performed using STATA version 16.0, with significance set at p < 0.05. Results: A total of 196 participants, which included 98 Tb cases (80 drug sensitive TB(DSTB),18multi drug resistant TB(MDRTB), and 98 controls, with a male:female ratio of1.13:1, mean age 33.82 ± 12.22 years, with an age range of 18-60 years, were recruited. After 90 days of anti-TB treatment, 4.1% of participants developed sensorineural hearing loss, with 3 cases classified as moderate seen among the MDRTB group and 1 case as mild among the DSTB group. There was no significant difference in mean pure tone hearing thresholds between the treatment and control groups in both ears (p = 0.395). Conclusion: Incidence of Bilateral demonstrable hearing loss after anti-TB drugs, which is common among MDRTB, has dropped with the introduction of all oral shorter regimens.
Indexed as
Identifiers
42471897PMC13379846What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.